ArticleFuture oncology (London, England)2025

Oncologists' preferences for first-line treatment of ALK-positive metastatic NSCLC in the United States: a discrete choice experiment.

Kathryn F Mileham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.